Crossmark

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

Crossref DOI link: https://doi.org/10.1038/s41392-025-02550-y

Published Online: 2026-02-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Fan

Zheng, Zhendong

Zhang, Hongmei

Yan, Xiaolong https://orcid.org/0000-0003-2419-9707
Liu, Zhefeng

Yang, Fan

Wen, Juyi

Gan, Xin

Wu, Lin https://orcid.org/0000-0001-7078-7767
Cang, Shundong

Wang, Hongmei

Zhao, Jun

Peng, Liang

Li, Xiaosong

Fan, Zaiwen

Shen, Ge

Zhou, Qiong https://orcid.org/0000-0002-3120-3017
Zou, Jinjing

Xu, Yu

Zhang, Lei

Zhao, Mingfang

Cai, Shangli https://orcid.org/0000-0002-5063-5712
Hu, Yi
Funding

Funding for this research was provided by:

National Health Commission capacity-building project
License Information

Text and Data Mining valid from 2026-02-02

Version of Record valid from 2026-02-02
More Information

Article History

Received: 6 June 2025

Revised: 26 November 2025

Accepted: 19 December 2025

First Online: 2 February 2026

Competing interests

: Yu Xu, Lei Zhang, and Shangli Cai are employees of Burning Rock Biotech. No other conflicts were reported.

Document is current

Any future updates will be listed below